FDA provides positive guidance to Ziopharm Oncology

Ziopharm Oncology Inc. (Nasdaq: ZIOP) received positive guidance from the Food and Drug Administration at its End-of-Phase 2 meeting for Ad-RTS-hIL-12 gene therapy candidate. The stock price gained 81 cents to close at $6.69.



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.